Eli Lilly and Company (NYSE: LLY) Stock Competitors & Peer Comparison

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, JNJ has a market cap of 650.6B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while JNJ trades at $269.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas JNJ's P/E ratio is 25.16. In terms of profitability, LLY's ROE is +0.93%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, LLY is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for LLY.Check JNJ's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, ABBV has a market cap of 466.1B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while ABBV trades at $263.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas ABBV's P/E ratio is 25.89. In terms of profitability, LLY's ROE is +0.93%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, LLY is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for LLY.Check ABBV's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, MRK has a market cap of 362.5B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while MRK trades at $146.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas MRK's P/E ratio is 45.72. In terms of profitability, LLY's ROE is +0.93%, compared to MRK's ROE of +0.07%. Regarding short-term risk, LLY is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for LLY.Check MRK's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, NVS has a market cap of 266.8B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while NVS trades at $140.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas NVS's P/E ratio is 16.15. In terms of profitability, LLY's ROE is +0.93%, compared to NVS's ROE of +0.30%. Regarding short-term risk, LLY is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for LLY.Check NVS's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, AZN has a market cap of 257.5B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while AZN trades at $166.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas AZN's P/E ratio is 17.93. In terms of profitability, LLY's ROE is +0.93%, compared to AZN's ROE of +0.22%. Regarding short-term risk, LLY is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for LLY.Check AZN's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, AMGN has a market cap of 205B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while AMGN trades at $385.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas AMGN's P/E ratio is 16.98. In terms of profitability, LLY's ROE is +0.93%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, LLY is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for LLY.Check AMGN's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, NVO has a market cap of 192B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while NVO trades at $43.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas NVO's P/E ratio is 10.76. In terms of profitability, LLY's ROE is +0.93%, compared to NVO's ROE of +0.59%. Regarding short-term risk, LLY is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for LLY.Check NVO's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, GILD has a market cap of 186.4B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while GILD trades at $150.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas GILD's P/E ratio is -384.90. In terms of profitability, LLY's ROE is +0.93%, compared to GILD's ROE of -0.16%. Regarding short-term risk, LLY is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for LLY.Check GILD's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, PFE has a market cap of 157.3B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while PFE trades at $27.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas PFE's P/E ratio is 9.05. In terms of profitability, LLY's ROE is +0.93%, compared to PFE's ROE of +0.05%. Regarding short-term risk, LLY is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for LLY.Check PFE's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, BMY has a market cap of 128.8B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while BMY trades at $63.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas BMY's P/E ratio is 10.63. In terms of profitability, LLY's ROE is +0.93%, compared to BMY's ROE of +0.47%. Regarding short-term risk, LLY is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for LLY.Check BMY's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, SNY has a market cap of 102B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while SNY trades at $42.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas SNY's P/E ratio is 9.25. In terms of profitability, LLY's ROE is +0.93%, compared to SNY's ROE of +0.06%. Regarding short-term risk, LLY is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for LLY.Check SNY's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, GSK has a market cap of 100.6B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while GSK trades at $50.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas GSK's P/E ratio is 10.85. In terms of profitability, LLY's ROE is +0.93%, compared to GSK's ROE of +0.24%. Regarding short-term risk, LLY is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for LLY.Check GSK's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, BIIB has a market cap of 31.8B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while BIIB trades at $215.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas BIIB's P/E ratio is 13.60. In terms of profitability, LLY's ROE is +0.93%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, LLY is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for LLY.Check BIIB's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas HZNP's P/E ratio is 61.86. In terms of profitability, LLY's ROE is +0.93%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, LLY is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for LLY.Check HZNP's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while GRFS trades at $7.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas GRFS's P/E ratio is 8.40. In terms of profitability, LLY's ROE is +0.93%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, LLY is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for LLY.Check GRFS's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while OGN trades at $13.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas OGN's P/E ratio is 4.09. In terms of profitability, LLY's ROE is +0.93%, compared to OGN's ROE of +0.23%. Regarding short-term risk, LLY is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for LLY.Check OGN's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, AMRN has a market cap of 286.9M. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while AMRN trades at $13.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas AMRN's P/E ratio is -138.70. In terms of profitability, LLY's ROE is +0.93%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, LLY is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for LLY.Check AMRN's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, SCLX has a market cap of 42.8M. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while SCLX trades at $5.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas SCLX's P/E ratio is -0.13. In terms of profitability, LLY's ROE is +0.93%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, LLY is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for LLY.Check SCLX's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, MIRA has a market cap of 34.2M. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while MIRA trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas MIRA's P/E ratio is -0.56. In terms of profitability, LLY's ROE is +0.93%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, LLY is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for LLY.Check MIRA's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, SCLXW has a market cap of 33.6M. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while SCLXW trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas SCLXW's P/E ratio is N/A. In terms of profitability, LLY's ROE is +0.93%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, LLY is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for LLY.Check SCLXW's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, LLY's ROE is +0.93%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, LLY is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for LLY.Check BDSIW's competition here

Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 1.1T. In comparison, CRXT has a market cap of 0. Regarding current trading prices, LLY is priced at $1,152.22 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 36.61, whereas CRXT's P/E ratio is -0.02. In terms of profitability, LLY's ROE is +0.93%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, LLY is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for LLY.Check CRXT's competition here